Journal article

PROGRESS - Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline

J Chalmers, S MacMahon, MG Bousser, C Tzourio, J Cutler, G Donnan, L Hansson, A Terent, S Harrap, S Davis, L Liu, G Mancia, R Sega, T Omae, J Reid, K Lees, A Rodgers, C Warlow

JOURNAL OF HYPERTENSION | LIPPINCOTT WILLIAMS & WILKINS | Published : 1999

Abstract

OBJECTIVE: The primary aim of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) is to determine the effects of a long-term angiotensin converting enzyme (ACE)-inhibitor-based blood-pressure-lowering regimen on the risk of stroke among patients with a history of stroke or transient ischaemic attack (TIA). Secondary aims include investigation of the effects of treatment on total cardiovascular events, dementia and disability. DESIGN AND METHODS: PROGRESS is a double-blind, placebo-controlled randomized trial. Patients were randomly assigned to treatment with the ACE inhibitor perindopril (and the diuretic indapamide for those with no definite indication or contraindication t..

View full abstract